Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
I Am Banking On The Silver Tsunami With Big Dividends
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Harrow Inc (HROW) Shares Up 3.26% on Oct 2
Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45.
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago.
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Harrow Successfully Manufactures Triesence; Management Credibility Soars
Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in $1.50 of incremental FCF/share in 2025, and then up from there, so that Triesence may by itself be worth more than the current share price. There are huge synergies with Iheezo, as the same buyers can be targeted for both drugs.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
